Company intelligence / Profile preview

Duplex Capital Partners

Ownership: Private
Development stage: Other

Overview

Duplex Capital Partners was established to invest in "digitally-based life science technology companies innovating to underpin the next generation of biotechnology products," focusing on the intersection of IT and biology ("TechBio"). The firm does not develop drugs or therapies itself but funds early-stage ventures that enable advances such as personalized medicine and data-driven drug discovery. Its approach aims at ESG impact by supporting technologies that lower costs and expand access for rare disease treatments. As of mid–2024 both its UK and Irish entities are inactive or being wound down.

Industry: Investors

Beyond the preview

Go deeper on Duplex Capital Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duplex Capital Partners.

Explore the full profile